Novel NRF2-activated cancer treatments utilizing synthetic lethality

被引：17

作者：

Baird, Liam ^{[1
,2
]}

Kensler, Thomas W. ^{[3
]}

Yamamoto, Masayuki ^{[1
,2
,4
]}

机构：

[1] Tohoku Univ, Dept Med Biochem, Grad Sch Med, Sendai, Miyagi, Japan

[2] Tohoku Univ, Adv Res Ctr Innovat Next Generat Med INGEM, Sendai, Miyagi, Japan

[3] Fred Hutchinson Canc Res Ctr, Translat Res Program, 1124 Columbia St, Seattle, WA 98104 USA

[4] Tohoku Univ, Tohoku Med Megabank Org, Sendai, Miyagi, Japan

来源：

IUBMB LIFE | 2022年 / 74卷 / 12期

基金：

日本学术振兴会;

关键词：

bioactivation; cancer; KEAP1; mitomycin C; NRF2; oxidative stress; prodrug; stress response; synthetic lethal; CELL LUNG-CANCER; COOCCURRING GENOMIC ALTERATIONS; TRANSCRIPTION FACTOR NRF2; PROTEIN; 90; INHIBITOR; PHASE-II TRIAL; MITOMYCIN-C; OXIDATIVE STRESS; BREAST-CANCER; HYDROCHLORIDE IPI-504; MUTATIONAL LANDSCAPE;

D O I：

10.1002/iub.2680

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The KEAP1-NRF2 pathway regulates the main inducible cellular response to oxidative and electrophilic stresses. Activating mutations in the KEAP1-NRF2 pathway occur commonly in human cancer, where they contribute to the formation of aggressive tumours that are associated with a poor prognosis for patients. An important clinical feature of these tumours is their defiance to all current anti-cancer treatment regimens, highlighting the need for the development of new therapeutic strategies to target NRF2-activated cancers. In this review, we discuss the mechanisms through which acquired NRF2 hyperactivation can result in resistance of tumours to immune checkpoint inhibitor therapies in addition to classical chemotherapeutics, and propose with examples that using a synthetic lethal strategy mediated by NRF2-target gene-dependent bioactivation of prodrugs represents a promising strategy to specifically enhance toxicity to heretofore untreatable NRF2-hyperactivated human tumours.

引用

页码：1209 / 1231

页数：23

共 205 条

[61] The biology and management of non-small cell lung cancer [J].

Herbst, Roy S. ;

Morgensztern, Daniel ;

Boshoff, Chris .

NATURE, 2018, 553 (7689) :446-454

[62]

HODNICK WF, 1993, CANCER RES, V53, P4907

[63] Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung Cancer [J].

Homma, Shinsuke ;

Ishii, Yukio ;

Morishima, Yuko ;

Yamadori, Tadahiro ;

Matsuno, Yosuke ;

Haraguchi, Norihiro ;

Kikuchi, Norihiro ;

Satoh, Hiroaki ;

Sakamoto, Tohru ;

Hizawa, Nobuyuki ;

Itoh, Ken ;

Yamamoto, Masayuki .

CLINICAL CANCER RESEARCH, 2009, 15 (10) :3423-3432

[64] Molecular basis for the disruption of Keap1-Nrf2 interaction via Hinge & Latch mechanism [J].

Horie, Yuta ;

Suzuki, Takafumi ;

Inoue, Jin ;

Iso, Tatsuro ;

Wells, Geoffrey ;

Moore, Terry W. ;

Mizushima, Tsunehiro ;

Dinkova-Kostova, Albena T. ;

Kasai, Takuma ;

Kamei, Takashi ;

Koshiba, Seizo ;

Yamamoto, Masayuki .

COMMUNICATIONS BIOLOGY, 2021, 4 (01)

[65] Nrf2 Overexpression Predicts Prognosis and 5-FU Resistance in Gastric Cancer [J].

Hu, Xiu-Feng ;

Yao, Jun ;

Gao, She-Gan ;

Wang, Xin-Shuai ;

Peng, Xiu-Qing ;

Yang, Yan-Tong ;

Feng, Xiao-Shan .

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (09) :5231-5235

[66] Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis [J].

Iida, K ;

Itoh, K ;

Kumagai, Y ;

Oyasu, R ;

Hattori, K ;

Kawai, K ;

Shimazui, T ;

Akaza, H ;

Yamamoto, M .

CANCER RESEARCH, 2004, 64 (18) :6424-6431

[67] Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma [J].

Inoue, Daisuke ;

Suzuki, Takashi ;

Mitsuishi, Yoichiro ;

Miki, Yasuhiro ;

Suzuki, Satoshi ;

Sugawara, Shunichi ;

Watanabe, Mika ;

Sakurada, Akira ;

Endo, Chiaki ;

Uruno, Akira ;

Sasano, Hironobu ;

Nakagawa, Takayuki ;

Satoh, Kennichi ;

Tanaka, Nobuyuki ;

Kubo, Hiroshi ;

Motohashi, Hozumi ;

Yamamoto, Masayuki .

CANCER SCIENCE, 2012, 103 (04) :760-766

[68] A Landscape of Pharmacogenomic Interactions in Cancer [J].

Iorio, Francesco ;

Knijnenburg, Theo A. ;

Vis, Daniel J. ;

Bignell, Graham R. ;

Menden, Michael P. ;

Schubert, Michael ;

Aben, Nanne ;

Goncalves, Emanuel ;

Barthorpe, Syd ;

Lightfoot, Howard ;

Cokelaer, Thomas ;

Greninger, Patricia ;

van Dyk, Ewald ;

Chang, Han ;

de Silva, Heshani ;

Heyn, Holger ;

Deng, Xianming ;

Egan, Regina K. ;

Liu, Qingsong ;

Mironenko, Tatiana ;

Mitropoulos, Xeni ;

Richardson, Laura ;

Wang, Jinhua ;

Zhang, Tinghu ;

Moran, Sebastian ;

Sayols, Sergi ;

Soleimani, Maryam ;

Tamborero, David ;

Lopez-Bigas, Nuria ;

Ross-Macdonald, Petra ;

Esteller, Manel ;

Gray, Nathanael S. ;

Haber, Daniel A. ;

Stratton, Michael R. ;

Benes, Cyril H. ;

Wessels, Lodewyk F. A. ;

Saez-Rodriguez, Julio ;

McDermott, Ultan ;

Garnett, Mathew J. .

CELL, 2016, 166 (03) :740-754

[69] Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain [J].

Itoh, K ;

Wakabayashi, N ;

Katoh, Y ;

Ishii, T ;

Igarashi, K ;

Engel, JD ;

Yamamoto, M .

GENES & DEVELOPMENT, 1999, 13 (01) :76-86

[70] An Nrf2 small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements [J].

Itoh, K ;

Chiba, T ;

Takahashi, S ;

Ishii, T ;

Igarashi, K ;

Katoh, Y ;

Oyake, T ;

Hayashi, N ;

Satoh, K ;

Hatayama, I ;

Yamamoto, M ;

Nabeshima, Y .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 236 (02) :313-322

← 2 3 4 5 6 7 8 9 10 11 →